US Patent

US9907756 — Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative

Formulation · Assigned to Boehringer Ingelheim International GmbH · Expires 2029-06-07 · 3y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a capsule pharmaceutical dosage form containing a suspension formulation of the indolinone derivative nintedanib esylate.

USPTO Abstract

The present invention relates to a suspension formulation containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate, to a capsule pharmaceutical dosage form containing said suspension formulation, to a process for preparing said suspension formulation, to a process for preparing said capsule comprising said suspension formulation and to the packaging material for the finished capsule.

Drugs covered by this patent

Patent Metadata

Patent number
US9907756
Jurisdiction
US
Classification
Formulation
Expires
2029-06-07
Drug substance claim
No
Drug product claim
Yes
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.